Stock Ideas
New
Stocks
Funds
Screener
Sectors
Watchlists
ELV

ELV - Elevance Health, Inc. Stock Price, Fair Value and News

547.88USD+3.99 (+0.73%)Market Closed

Market Summary

ELV
USD547.88+3.99
Market Closed
0.73%

ELV Alerts

  • 1 major insider sales recently.

ELV Stock Price

View Fullscreen

ELV RSI Chart

ELV Valuation

Market Cap

127.4B

Price/Earnings (Trailing)

20.4

Price/Sales (Trailing)

0.74

EV/EBITDA

13.39

Price/Free Cashflow

55.49

ELV Price/Sales (Trailing)

ELV Profitability

EBT Margin

4.68%

Return on Equity

15.38%

Return on Assets

5.58%

Free Cashflow Yield

1.8%

ELV Fundamentals

ELV Revenue

Revenue (TTM)

171.7B

Rev. Growth (Yr)

0.96%

Rev. Growth (Qtr)

-0.16%

ELV Earnings

Earnings (TTM)

6.2B

Earnings Growth (Yr)

12.92%

Earnings Growth (Qtr)

162.84%

Breaking Down ELV Revenue

Last 7 days

1.6%

Last 30 days

7.6%

Last 90 days

6.9%

Trailing 12 Months

20.4%

How does ELV drawdown profile look like?

ELV Financial Health

Current Ratio

1.37

Debt/Equity

0.54

Debt/Cashflow

0.16

ELV Investor Care

Dividend Yield

1.11%

Dividend/Share (TTM)

6.07

Buy Backs (1Y)

1.93%

Diluted EPS (TTM)

26.5

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2024171.7B000
2023160.7B165.7B168.6B171.3B
2022144.3B149.1B153.2B156.6B
2021124.6B129.2B133.9B138.6B
2020109.2B113.0B117.5B121.9B
201994.2B96.8B100.2B104.2B
201890.1B90.6B91.4B92.1B
201787.1B88.1B89.1B90.0B
201680.4B81.8B83.3B84.9B
201575.1B76.6B78.0B79.2B
201471.3B72.1B72.8B73.9B
201363.7B66.0B68.6B71.0B
201261.2B61.5B61.4B61.5B
201158.5B59.2B60.0B60.7B
201065.0B64.0B63.1B58.7B
200960.8B60.6B61.1B65.0B
2008061.2B61.2B61.3B
200700061.2B
GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed S&P 500 Index

Grufity's Fair Value model takes all the S&P 500 stocks and divides them into separate buckets based on their attractiveness. The 'Very Cheap' bucket of S&P 500 has greatly outperformed S&P 500 Index. Conversely, S&P500 stocks considered 'Very Expensive' by the model underperformed the S&P500 index in the past three years. Grufity Fair Value is available for 2300+ stocks, including 90% of S&P 500 stocks. Grufity's Fair Value Model separates high-return stocks from low-return stocks.

PurpleZone


Returns of $10,000 invested in:

Very Cheap Stocks: $17,289
S&P 500 Index: $12,922
Very Expensive Stocks: $11,022


Grufity's Fair Value model does a great job in separating High Performing Stocks from Low Performing ones in the S&P 500 list.

S&P 500 Index
Very Expensive Stocks
Very Cheap Stocks
Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Elevance Health, Inc.

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Apr 24, 2024
norwood felicia f
acquired
486,786
238
2,043
evp & president,gov health ben
Apr 24, 2024
norwood felicia f
sold
-3,300,590
532
-6,199
evp & president,gov health ben
Apr 23, 2024
norwood felicia f
sold
-7,531,560
533
-14,111
evp & president,gov health ben
Apr 23, 2024
norwood felicia f
acquired
1,304,050
238
5,473
evp & president,gov health ben
Mar 08, 2024
kendrick charles morgan jr
sold
-1,217,120
500
-2,432
evp & president, commercial
Mar 06, 2024
penczek ronald w
sold
-462,195
504
-916
cao & controller
Mar 04, 2024
haytaian peter d
sold
-10,551,300
500
-21,095
evp & pres carelon & carelonrx
Mar 04, 2024
haytaian peter d
acquired
2,504,550
166
15,000
evp & pres carelon & carelonrx
Mar 01, 2024
boudreaux gail
sold (taxes)
-9,610,860
499
-19,256
president and ceo
Mar 01, 2024
kendrick charles morgan jr
acquired
-
-
4,508
evp & president, commercial

1–10 of 50

Which funds bought or sold ELV recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
May 17, 2024
New Covenant Trust Company, N.A.
new
-
90,745
90,745
0.09%
May 17, 2024
Lummis Asset Management, LP
unchanged
-
846
9,334
0.01%
May 17, 2024
VIMA LLC
new
-
223,468
223,468
0.17%
May 17, 2024
Plato Investment Management Ltd
added
437
2,518,330
3,031,380
0.31%
May 17, 2024
Kozak & Associates, Inc.
reduced
-37.01
-66,572
174,041
0.05%
May 17, 2024
Aspect Partners, LLC
unchanged
-
1,457
16,075
0.01%
May 17, 2024
CITIZENS FINANCIAL GROUP INC/RI
added
2.63
85,487
749,776
0.03%
May 16, 2024
FSA Wealth Management LLC
unchanged
-
741
6,741
-%
May 16, 2024
Arete Wealth Advisors, LLC
sold off
-100
-456,546
-
-%
May 16, 2024
First Western Trust Bank
reduced
-4.99
23,720
553,282
0.03%

1–10 of 46

Are Funds Buying or Selling ELV?

Are funds buying ELV calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own ELV
No. of Funds

Unveiling Elevance Health, Inc.'s Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2024
price t rowe associates inc /md/
5.1%
11,929,862
SC 13G
Feb 13, 2024
vanguard group inc
9.03%
21,227,022
SC 13G/A
Feb 12, 2024
blackrock inc.
9.0%
21,044,185
SC 13G/A
Feb 14, 2023
price t rowe associates inc /md/
5.3%
12,717,041
SC 13G
Feb 09, 2023
vanguard group inc
8.99%
21,473,444
SC 13G/A
Jan 27, 2023
blackrock inc.
9.0%
21,566,516
SC 13G/A
Jan 25, 2023
blackrock inc.
9.0%
21,566,516
SC 13G/A

Recent SEC filings of Elevance Health, Inc.

View All Filings
Date Filed Form Type Document
May 17, 2024
4
Insider Trading
May 17, 2024
4
Insider Trading
May 17, 2024
4
Insider Trading
May 17, 2024
4
Insider Trading
May 17, 2024
4
Insider Trading
May 17, 2024
4
Insider Trading
May 17, 2024
4
Insider Trading
May 17, 2024
4
Insider Trading
May 17, 2024
4
Insider Trading
May 17, 2024
4
Insider Trading

Elevance Health, Inc. News

Latest updates
MarketBeat12 hours ago
MarketBeat16 May 202407:53 am
Yahoo Finance10 May 202401:45 pm
Yahoo Finance09 May 202407:00 am

Elevance Health, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
(In Millions)
Income Statement (Quarterly)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Revenue-0.2%42,57742,64742,84943,67242,17239,92939,93938,63238,09536,58135,82233,85132,38531,82431,15829,26429,62127,40726,67425,46624,666
  S&GA Expenses-2.3%4,8864,9995,4704,8184,8004,5674,5164,2724,3454,2263,9463,8213,9254,3185,3054,0463,7813,5023,4183,2783,166
EBITDA Margin1.7%0.06*0.06*0.06*0.07*0.07*0.06*0.07*0.07*0.07*0.07*0.07*0.06*0.07*0.07*0.07*0.09*0.07*----
Interest Expenses2.3%265259259261251229213208201200201205192191198201194190185184187
Income Taxes305.9%69017035458561516852948852729149455250960.00167873566164306314394
Earnings Before Taxes193.6%2,9391,0011,6542,4412,6191,0452,1272,1222,3061,4701,9962,3532,1766113893,1492,0891,0981,4891,4531,945
EBT Margin3.9%0.05*0.05*0.05*0.05*0.05*0.05*0.05*0.05*0.06*0.06*0.05*0.04*0.05*0.05*0.06*0.07*0.06*----
Net Income162.8%2,2468551,2891,8561,9898721,6031,6341,7791,1861,5091,8011,6675512222,2761,5239341,1831,1391,551
Net Income Margin4.0%0.04*0.03*0.04*0.04*0.04*0.04*0.04*0.04*0.04*0.04*0.04*0.03*0.04*0.04*0.04*0.05*0.04*----
Free Cashflow151.5%1,699-3,2972,2941,6006,168-1,8164,6192,1572,2871,3322,2461,3982,3013,535-1,4565,2772,311----
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Assets2.7%111,894108,928110,478109,168109,040102,755103,026100,877100,48697,45698,06096,09795,68386,61586,57487,97682,39977,45377,80975,85174,523
  Current Assets1.5%60,94860,02961,18559,74359,82355,61755,60353,65553,89751,12251,90450,23854,49545,75145,45046,76441,25639,03339,50437,80536,611
    Cash Equivalents-4.6%6,2266,52610,9199,99110,1427,3878,8726,4566,1614,8805,4905,2589,3265,7413,9846,0285,3454,9374,1904,0784,482
  Net PPE2.1%4,4514,3594,2484,5474,4184,3164,1974,0903,9863,9193,8353,7333,5333,4833,3633,4273,3503,1332,9212,8372,799
  Goodwill2.5%25,94725,31725,29125,27425,27324,38324,38124,36724,25124,22824,18424,39921,70821,69121,68721,64121,66120,50020,50020,50020,500
Liabilities2.4%71,18469,52371,93970,85671,58066,42566,98365,01064,45561,29362,25261,05161,76553,41652,65353,52150,70645,72546,47745,05844,525
  Current Liabilities6.1%44,33441,79143,33741,57141,88939,69641,28739,30839,73334,88535,16233,79434,74929,45328,56128,52227,03923,53223,23423,09022,682
  Short Term Borrowings600.0%1,575225-265265265265175275275175175--150-1,0757007101,0101,095
  Long Term Debt-5.5%21,97623,24624,04524,85925,20122,34921,25821,16519,88321,15721,76122,21722,53419,33519,09419,87319,00517,78718,82017,43617,396
    LT Debt, Current75.9%2,9001,649799--1,5002,2492,2483,0971,5998498497007001,5991,6031,6031,598700850851
    LT Debt, Non Current-5.5%21,97623,24624,04524,85925,20122,34921,25821,16519,88321,15721,76122,21722,53419,33519,09419,87319,00517,78718,82017,43617,396
Shareholder's Equity3.3%40,60839,30638,42338,31237,46036,33036,05535,88736,05936,16335,80835,04633,91833,18733,92134,45531,69331,69331,33230,79329,998
  Retained Earnings4.2%33,08831,74932,10331,60830,70729,64729,60428,82528,05827,14226,70025,87424,79323,80224,67825,34623,36022,57322,10421,67921,136
  Additional Paid-In Capital0.2%8,8838,8688,8308,7618,6979,0849,1699,1349,1519,1489,1389,1099,2539,2449,3529,3609,3389,4489,5249,4949,482
Shares Outstanding-0.2%233233235236237238239240241242243244245245249252252----
Minority Interest3.0%10299.0011610710487.0052.0055.0056.0068.0071.0078.0065.00--------
Float----104,634---115,692---93,008---66,231---72,160-
Cashflow (Last 12 Months)
(In Millions)
Cashflow (Quarterly)
(In Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Cashflow From Operations166.6%1,978-2,9712,6131,9506,469-1,5184,9242,4522,5411,6722,5041,6832,5053,813-1,1505,5102,5151,3271,6671,4371,630
  Share Based Compensation-13.9%62.0072.0078.0078.0061.0073.0069.0072.0050.0059.0063.0069.0064.0069.0080.0067.0067.0068.0086.0070.0070.00
Cashflow From Investing-124.5%-2,310-1,029-687-672-3,184289-1,247-2,024-1,578-966-1,440-4,925-2,30730589.00-4,934-2,784723-1,698-1,165-652
Cashflow From Financing108.1%32.00-394-994-1,430-531-258-1,255-127322-1,315-830-8203,388-2,367-984105679-1,304144-677-429
  Dividend Payments9.5%379346348350351305306309309273276278277234238242240202204206206
  Buy Backs-38.6%5669234856526225685796245455224514804471,35875855.00529305644458294
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

ELV Income Statement

2024-03-31
Consolidated Statements of Income - USD ($)
$ in Millions
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Revenues  
Premiums$ 35,696$ 35,868
Total operating revenue42,27341,898
Net investment income465387
Net losses on financial instruments(161)(113)
Total revenues42,57742,172
Expenses  
Benefit expense30,54630,786
Cost of products sold3,8253,481
Operating expense4,8864,800
Interest expense265251
Amortization of other intangible assets116235
Total expenses39,63839,553
Income before income tax expense2,9392,619
Income tax expense690615
Net income2,2492,004
Net income attributable to noncontrolling interests(3)(15)
Shareholders’ net income$ 2,246$ 1,989
Shareholders’ net income per share  
Basic (in dollars per share)$ 9.65$ 8.37
Diluted (in dollars per share)9.598.30
Dividends per share (in dollars per share)$ 1.63$ 1.48
Product revenue  
Revenues  
Product and service revenue$ 4,499$ 4,022
Service fees  
Revenues  
Product and service revenue$ 2,078$ 2,008

ELV Balance Sheet

2024-03-31
Consolidated Balance Sheets - USD ($)
$ in Millions
Mar. 31, 2024
Dec. 31, 2023
Current assets:  
Cash and cash equivalents$ 6,226$ 6,526
Fixed maturity securities (amortized cost of $30,427 and $30,446; allowance for credit losses of $4 and $4)29,53029,614
Equity securities511229
Premium receivables8,9317,902
Self-funded receivables4,2424,558
Other receivables5,1205,405
Other current assets6,3885,795
Total current assets60,94860,029
Long-term investments:  
Fixed maturity securities (amortized cost of $902 and $890; allowance for credit losses of $0 and $0)880876
Other invested assets6,7136,107
Property and equipment, net4,4514,359
Goodwill25,94725,317
Other intangible assets10,71010,273
Other noncurrent assets2,2451,967
Total assets111,894108,928
Current liabilities:  
Medical claims payable16,45916,111
Other policyholder liabilities5,2985,600
Unearned income1,4741,402
Accounts payable and accrued expenses5,6586,910
Short-term borrowings1,575225
Current portion of long-term debt2,9001,649
Other current liabilities10,9709,894
Total current liabilities44,33441,791
Long-term debt, less current portion21,97623,246
Reserves for future policy benefits765778
Deferred tax liabilities, net2,2011,970
Other noncurrent liabilities1,9081,738
Total liabilities71,18469,523
Commitments and contingencies – Note 11
Shareholders’ equity  
Preferred stock, without par value, shares authorized – 100,000,000; shares issued and outstanding – none00
Common stock, par value $0.01, shares authorized – 900,000,000; shares issued and outstanding – 232,544,717 and 233,071,08822
Additional paid-in capital8,8838,868
Retained earnings33,08831,749
Accumulated other comprehensive loss(1,365)(1,313)
Total shareholders’ equity40,60839,306
Noncontrolling interests10299
Total equity40,71039,405
Total liabilities and equity$ 111,894$ 108,928
ELV
Elevance Health, Inc. operates as a health benefits company. The company operates through four segments: Commercial & Specialty Business, Government Business, CarelonRx, and Other. It supports consumers, families, and communities across the entire care journey connecting to the care, support, and resources to lead healthier lives. It serves people through a portfolio of medical, digital, pharmacy, behavioral, clinical, and care solutions. The company was formerly known as Anthem, Inc. and changed its name to Elevance Health, Inc. in June 2022. Elevance Health, Inc. was founded in 1944 and is based in Indianapolis, Indiana.
 CEO
 WEBSITEelevancehealth.com
 INDUSTRYHealthcare Plans
 EMPLOYEES65535

Elevance Health, Inc. Frequently Asked Questions


What is the ticker symbol for Elevance Health, Inc.? What does ELV stand for in stocks?

ELV is the stock ticker symbol of Elevance Health, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Elevance Health, Inc. (ELV)?

As of Fri May 17 2024, market cap of Elevance Health, Inc. is 127.41 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ELV stock?

You can check ELV's fair value in chart for subscribers.

What is the fair value of ELV stock?

You can check ELV's fair value in chart for subscribers. The fair value of Elevance Health, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Elevance Health, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ELV so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Elevance Health, Inc. a good stock to buy?

The fair value guage provides a quick view whether ELV is over valued or under valued. Whether Elevance Health, Inc. is cheap or expensive depends on the assumptions which impact Elevance Health, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ELV.

What is Elevance Health, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, ELV's PE ratio (Price to Earnings) is 20.4 and Price to Sales (PS) ratio is 0.74. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ELV PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Elevance Health, Inc.'s stock?

In the past 10 years, Elevance Health, Inc. has provided 0.192 (multiply by 100 for percentage) rate of return.